HCT-ASCT confirmed as standard-of-care consolidation therapy for PCNSL [0.03%]
HCT-ASCT确认成为PCNSL标准巩固疗法
David Killock
David Killock
Andrea Villa,Ashley L Eadie,David Synnott et al.
Andrea Villa et al.
Oncology clinical trials are often characterized by slow accrual, high failure rates and limited generalizability, reflecting both biological complexity and operational inefficiencies. Advances in artificial intelligence (AI) - enabled by l...
More options, more questions in the management of early relapsed and/or refractory multiple myeloma [0.03%]
复发和/或难治性多发性骨髓瘤早期治疗选择及疑问更多了
Carlyn Rose Tan,Sham Mailankody
Carlyn Rose Tan
Clinical toxicity of ADCs and ICI-ADC combinations: mechanisms, patterns and management [0.03%]
抗体药物偶联物和免疫检查点抑制剂抗体药物偶联物联合用药的临床毒性：机制、模式和管理
Solange Peters,Petros Grivas,Christophe Massard et al.
Solange Peters et al.
Antibody-drug conjugates (ADCs) and immune checkpoint inhibitors (ICIs) have reshaped cancer therapy both as monotherapy and in combination. However, these drug classes have toxicity profiles that, despite arising from different biological ...
Hira Mian,Luciano J Costa,Mohamad Mohty et al.
Hira Mian et al.
De-escalation of therapy constitutes a new phase in the development of therapeutic approaches for patients with multiple myeloma (MM) and is aimed at maintaining durable disease control while reducing the toxicity and burden associated with...
Klaus Pantel,Doryan Masmoudi,Catherine Alix-Panabières
Klaus Pantel
Analysis of tissue biopsy samples is the gold-standard approach to cancer diagnosis and patient selection for biomarker-guided therapies. Although spatial analyses of tumour tissue can provide important insights into local antitumour immune...